AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29379095 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study 27162089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir 150 mg (30 mg × 5 tablets) every 12 hours for a total of 3 doses over 2 days
Number of subjects: 0
Study 27162089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching cabotegravir) every 12 hours for 2 days
Number of subjects: 0
Study 27162089 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (single open-label dose)
Number of subjects: 0
Study 24956384 — intervention group
Group type: EXPERIMENTAL
Intervention: More appropriate prosthesis
Number of subjects: 24
Study 24956384 — intervention group
Group type: EXPERIMENTAL
Intervention: Less appropriate prosthesis
Number of subjects: 24
Study 24956384 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptation period
Number of subjects: 24
Study 24956384 — intervention group
Group type: EXPERIMENTAL
Intervention: Midpoint of adaptation period
Number of subjects: 24
Study 24956384 — intervention group
Group type: EXPERIMENTAL
Intervention: End of adaptation period
Number of subjects: 24
Study 24956384 — intervention group
Group type: COMPARATOR
Intervention: Initial fitting
Number of subjects: 24
Study 22688340 — intervention group
Group type: EXPERIMENTAL
Intervention: standard control to range (sCTR)
Number of subjects: 38
Study 22688340 — intervention group
Group type: EXPERIMENTAL
Intervention: enhanced control to range (eCTR)
Number of subjects: 38
Study 22688340 — intervention group
Group type: COMPARATOR
Intervention: CSII (Control)
Number of subjects: 38
Study 20883926 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 1191
Study 20883926 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest coenzyme Q₁₀ tertile
Number of subjects: 1191
Study 20883926 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q₁₀
Number of subjects: 1191
Study 19458395 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lens electrical stimulation of one eye
Number of subjects: 17
Study 19458395 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT) imaging
Number of subjects: 17
Study 19458395 — intervention group
Group type: COMPARATOR
Intervention: Comparison to normal controls
Number of subjects: 17
Study 16451856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.2 ppm) for 4 hr for 4 consecutive days (4D)
Number of subjects: 15
Study 16451856 — intervention group
Group type: COMPARATOR
Intervention: Ozone (0.2 ppm) for 4 hr for 1 day (1D)
Number of subjects: 15
Study 15136379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg bid)
Number of subjects: 23
Study 15136379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 11299153 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 80
Study 11299153 — intervention group
Group type: COMPARATOR
Intervention: Traditional Course
Number of subjects: 80
Study 9494320 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,800 cGy whole brain radiation therapy (WBRT) plus intrathecal methotrexate (IT MTX)
Number of subjects: 0
Study 9494320 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal methotrexate (IT MTX) alone
Number of subjects: 0
Study 8516054 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg)
Number of subjects: 63
Study 8516054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 3326926 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH nasal spray (400 micrograms three times a day for 28 days)
Number of subjects: 237
Study 3326926 — intervention group
Group type: COMPARATOR
Intervention: Orchiopexy (surgical intervention)
Number of subjects: 237
Study 31870562 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplement drink enriched with omega-3 fatty acids and vitamin D plus additional olive oil and olive oil-based spread
Number of subjects: 111
Study 31870562 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (not specified)
Number of subjects: 111
Study 29276990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) plus care as usual
Number of subjects: 62
Study 29276990 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen
Number of subjects: 62
Study 29276990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 62
Study 29276990 — intervention group
Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 62
Study 27244789 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (NBS) - Boys (n = 22)
Number of subjects: 107
Study 27244789 — intervention group
Group type: COMPARATOR
Intervention: Control group - Boys (n = 19)
Number of subjects: 107
Study 27244789 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (NBS) - Girls (n = 10)
Number of subjects: 107
Study 27244789 — intervention group
Group type: COMPARATOR
Intervention: Control group - Girls (n = 13)
Number of subjects: 107
Study 27244789 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened group (NBS)
Number of subjects: 107
Study 27244789 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 107
Study 24917333 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aid provided
Number of subjects: 64
Study 24917333 — intervention group
Group type: COMPARATOR
Intervention: Control (no cognitive aid)
Number of subjects: 64
Study 22858745 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg INK
Number of subjects: 12
Study 22858745 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg INK
Number of subjects: 12
Study 22858745 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg/kg INK
Number of subjects: 12
Study 22858745 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 21207769 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized protocol-driven verbal and written education with caregiver present using motivational interviewing techniques
Number of subjects: 20
Study 21207769 — intervention group
Group type: COMPARATOR
Intervention: Standard of care: verbal and written education at the time of discharge by the discharge nurse
Number of subjects: 20
Study 18502003 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA‐C priming (4 mg/ml) given intramuscularly at weeks 0 and 4 plus NYVAC‐C at weeks 20 and 24
Number of subjects: 35
Study 18502003 — intervention group
Group type: COMPARATOR
Intervention: NYVAC‐C alone
Number of subjects: 35
Study 15316827 — intervention group
Group type: EXPERIMENTAL
Intervention: PSteE-milk (2.0 g plant sterols/d)
Number of subjects: 79
Study 15316827 — intervention group
Group type: EXPERIMENTAL
Intervention: PSteE-spread (4 g plant sterols/d)
Number of subjects: 79
Study 15316827 — intervention group
Group type: EXPERIMENTAL
Intervention: PSteE-yoghurt (1.8 g plant sterols/d)
Number of subjects: 79
Study 15316827 — intervention group
Group type: EXPERIMENTAL
Intervention: PStaE-yoghurt (1.7 g plant stanols/d)
Number of subjects: 79
Study 15316827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PSteE-milk and PSteE-spread
Number of subjects: 79
Study 15316827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 12731428 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with simultaneous embolic protection
Number of subjects: 171
Study 12731428 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 171
Study 10497456 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (25 micrograms with 12 mg of hyperbaric bupivacaine 0.75%)
Number of subjects: 50
Study 10497456 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free normal saline (0.5 mL with 12 mg of hyperbaric bupivacaine 0.75%)
Number of subjects: 50
Study 8947070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 400 microg x day(-1)
Number of subjects: 229
Study 8947070 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) 400 microg x day(-1)
Number of subjects: 229
Study 1836438 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 15
Study 1836438 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy
Number of subjects: 15
Study 1836438 — intervention group
Group type: COMPARATOR
Intervention: YAG laser, Argon laser, Electrocautery
Number of subjects: 15
Study 7126515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular extraction
Number of subjects: 33
Study 7126515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular extraction plus Federov 4‐loop iris clip lens
Number of subjects: 33
Study 7126515 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular extraction with Binkhorst 2‐loop iridocapsular lens
Number of subjects: 33
Study 31795162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient-dense (ND) breakfast meal
Number of subjects: 30
Study 31795162 — intervention group
Group type: COMPARATOR
Intervention: Energy-dense (ED) breakfast meal
Number of subjects: 30
Study 27763685 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 139
Study 27763685 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise programme (SEP)
Number of subjects: 139
Study 27763685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (PTA + SEP)
Number of subjects: 139
Study 27763685 — intervention group
Group type: COMPARATOR
Intervention: Control group (SEP)
Number of subjects: 139
Study 26552742 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary portfolio (n = 159)
Number of subjects: 241
Study 26552742 — intervention group
Group type: COMPARATOR
Intervention: DASH-type diet (control n = 82)
Number of subjects: 241
Study 24388737 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.1 μg/kg/min and demand boluses of 0.1 μg/kg
Number of subjects: 60
Study 24388737 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 24388737 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 60
Study 21084969 — intervention group
Group type: EXPERIMENTAL
Intervention: Work day
Number of subjects: 37
Study 19177029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetics-guided dosing for warfarin therapy
Number of subjects: 156
Study 19177029 — intervention group
Group type: COMPARATOR
Intervention: Traditional dosing for warfarin therapy
Number of subjects: 156
Study 17640542 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatment with combination of antiplatelet and anticoagulant therapy, early coronary angiography, revascularization, and anti-ischemic medical therapy.
Number of subjects: 0
Study 17640542 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive risk-factor control after the acute event.
Number of subjects: 0
Study 15274397 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate-modulated continuous infusion of 5-fluorouracil (ci5-FU/MTX)
Number of subjects: 32
Study 15274397 — intervention group
Group type: COMPARATOR
Intervention: Raltitrexed
Number of subjects: 32
Study 11762659 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (500 units, five tablets per day)
Number of subjects: 100
Study 11762659 — intervention group
Group type: COMPARATOR
Intervention: Placebo (five placebo tablets per day)
Number of subjects: 100
Study 8994754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime/amikacin
Number of subjects: 353
Study 8994754 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime/amikacin
Number of subjects: 353
Study 8220143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mitozantrone and ifosfamide
Number of subjects: 34
Study 8220143 — intervention group
Group type: COMPARATOR
Intervention: Single agent mitozantrone
Number of subjects: 34
Study 3602025 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride (5 mg/kg/day, oral route)
Number of subjects: 0
Study 3602025 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride (intravenous and oral routes)
Number of subjects: 0
Study 3602025 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31108355 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor areas of public venues
Number of subjects: 17737
Study 31108355 — intervention group
Group type: COMPARATOR
Intervention: Outdoor areas around schools
Number of subjects: 17737
Study 28107540 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + Decision Aid (DA)
Number of subjects: 51
Study 28107540 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 51
Study 25873152 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stretch inelastic compression bandage for 24 hours after surgery
Number of subjects: 50
Study 25873152 — intervention group
Group type: COMPARATOR
Intervention: Standard wool and crepe bandage
Number of subjects: 50
Study 25873152 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stretch inelastic compression bandage
Number of subjects: 50
Study 23401447 — intervention group
Group type: EXPERIMENTAL
Intervention: Elesclomol 213 mg/m2 plus paclitaxel 80 mg/m2
Number of subjects: 651
Study 23401447 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m2 alone
Number of subjects: 651
Study 23401447 — intervention group
Group type: EXPERIMENTAL
Intervention: Elesclomol plus paclitaxel in patients with normal baseline LDH
Number of subjects: 651
Study 23401447 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone in patients with high LDH levels
Number of subjects: 651
Study 21517230 — intervention group
Group type: EXPERIMENTAL
Intervention: Education based on the Health Belief Model
Number of subjects: 0
Study 21517230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 0
Study 18554591 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-gas system (5% O2, 6% CO2, 90% N2)
Number of subjects: 396
Study 18554591 — intervention group
Group type: COMPARATOR
Intervention: Two-gas system (19% O2, 6% CO2)
Number of subjects: 396
Study 17635382 — intervention group
Group type: EXPERIMENTAL
Intervention: fermented milk containing Bifidobacterium animalis DN-173 010
Number of subjects: 274
Study 17635382 — intervention group
Group type: COMPARATOR
Intervention: heat-treated yoghurt (control)
Number of subjects: 274
Study 15217814 — intervention group
Group type: EXPERIMENTAL
Intervention: IC‐Clustering
Number of subjects: 0
Study 15217814 — intervention group
Group type: COMPARATOR
Intervention: k‐means method
Number of subjects: 0
Study 12970637 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 30
Study 12970637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9830247 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 0
Study 9830247 — intervention group
Group type: COMPARATOR
Intervention: Other groups (non-PTSD)
Number of subjects: 0
Study 8087352 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and oral endotracheal intubation with gastric intubation performed via the same route in Group 1 patients
Number of subjects: 162
Study 8087352 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal and gastric tubes left in original position in Group 2 patients
Number of subjects: 162
Study 8087352 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal puncture for bacteriologic analysis of maxillary sinus content in Group 3 patients
Number of subjects: 162
Study 8087352 — intervention group
Group type: COMPARATOR
Intervention: Control group of 45 spontaneously breathing patients
Number of subjects: 162
Study 8087352 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 patients
Number of subjects: 162
Study 2767860 — intervention group
Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole cell (BS‐WC) oral cholera vaccine
Number of subjects: 62285
Study 2767860 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole cell‐only (WC) oral cholera vaccine
Number of subjects: 62285
Study 2767860 — intervention group
Group type: COMPARATOR
Intervention: Exclusion of mixed infections with V. cholerae 01
Number of subjects: 62285
Study 1221432 — intervention group
Group type: EXPERIMENTAL
Intervention: delta9-THC (25 mg)
Number of subjects: 5
Study 1221432 — intervention group
Group type: EXPERIMENTAL
Intervention: CBN (50 mg)
Number of subjects: 5
Study 1221432 — intervention group
Group type: EXPERIMENTAL
Intervention: delta9-THC (25 mg) + CBN (50 mg)
Number of subjects: 5
Study 1221432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30365009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 769
Study 30365009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study 28170356 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 217
Study 28170356 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-Y-Gastric Bypass (LRYGB)
Number of subjects: 217
Study 25500330 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided hepaticogastrostomy (HPG)
Number of subjects: 49
Study 25500330 — intervention group
Group type: COMPARATOR
Intervention: EUS-guided choledochoduodenostomy (CD)
Number of subjects: 49
Study 23429495 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly with gemcitabine
Number of subjects: 38
Study 23429495 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone (Control)
Number of subjects: 38
Study 21420063 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (saline group, n = 189)
Number of subjects: 382
Study 21420063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (bicarbonate group, n = 193)
Number of subjects: 382
Study 21420063 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (saline group)
Number of subjects: 382
Study 21420063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (bicarbonate group)
Number of subjects: 382
Study 21420063 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride and sodium bicarbonate
Number of subjects: 382
Study 19283597 — intervention group
Group type: EXPERIMENTAL
Intervention: PrimeTime
Number of subjects: 145
Study 19283597 — intervention group
Group type: COMPARATOR
Intervention: Lunch Buddy
Number of subjects: 145
Study 17954538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (informing about entitled services)
Number of subjects: 1045
Study 15534159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline combined with transdermal nicotine (nortriptyline started at 25 mg, titrated to 75 mg/d for 12 weeks; transdermal nicotine at 21 mg/d for 8 weeks)
Number of subjects: 158
Study 15534159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched placebo for nortriptyline)
Number of subjects: 158
Study 11575536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (50 mg/kg bolus followed by 15 mg x kg(‐1) x h(‐1) for 6 h)
Number of subjects: 60
Study 11575536 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 60
Study 11575536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 60
Study 9778981 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional military training of women
Number of subjects: 110
Study 9778981 — intervention group
Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 110
Study 7810638 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (antilipolytic agent)
Number of subjects: 7
Study 7810638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2817186 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Risk Appraisal (HRA)
Number of subjects: 338
Study 2817186 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-scored instruments
Number of subjects: 338
Study 2817186 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up period (7 to 12 weeks)
Number of subjects: 338
Study 786686 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (45 mg Zn++) with tetracycline hydrochloride (500 mg)
Number of subjects: 7
Study 786686 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (45 mg Zn++) with doxycycline chloride (200 mg)
Number of subjects: 7
Study 31004853 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 181
Study 31004853 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA)
Number of subjects: 181
Study 31004853 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tranexamic acid (TXA)
Number of subjects: 181
Study 31004853 — intervention group
Group type: COMPARATOR
Intervention: All groups (including intravenous, topical, and combined)
Number of subjects: 181
Study 28911008 — intervention group
Group type: EXPERIMENTAL
Intervention: High quintile of arginine intake
Number of subjects: 7591
Study 28911008 — intervention group
Group type: COMPARATOR
Intervention: Low quintile of arginine intake
Number of subjects: 7591
Study 28911008 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine intake (continuous association)
Number of subjects: 7591
Study 28911008 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine intake
Number of subjects: 7591
Study 26250495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 488
Study 26250495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study 26250495 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Group 3 PH
Number of subjects: 488
Study 26250495 — intervention group
Group type: COMPARATOR
Intervention: Subjects with IPF and no PH
Number of subjects: 488
Study 26250495 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 488
Study 26250495 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with IPF and WHO Group 3 PH
Number of subjects: 488
Study 23200272 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ 140 mg/d
Number of subjects: 0
Study 23200272 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ 70 mg/d
Number of subjects: 0
Study 23200272 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ 140 mg/d and TMZ 70 mg/d
Number of subjects: 0
Study 23200272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0